Navigation Links
Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses
Date:10/19/2007

WINSTON-SALEM, N.C., Oct. 19 /PRNewswire/ -- Pilot Therapeutics Inc., a Nutritional Therapeutics Innovation Company, today announced the appointment of Ross Consaul as CEO and Keith Wakeman as President.

"Pilot has always had promising technology and patents in the food, medical food and dietary supplement areas with over 60 issued and pending patents. These new additions will unlock the potential to rapidly move our world class technologies and IP to the marketplace," said Dr. Floyd "Ski" Chilton, Founder and Chief Technology Officer of Pilot Therapeutics Inc.

Ross joins Pilot with over 20 years experience leading New Ventures, R&D, and New Product Development for large and small companies including Bayer, Kellogg, Pizza Hut and Kashi. He was most recently Nutrition General Manager for Bayer BioScience where he was responsible for identifying and creating new health and nutrition businesses for Bayer.

Keith brings over 20 years of management experience in the food and nutrition industry leading Marketing, Innovation and New Ventures organizations for major companies including Kellogg, Keebler and Nabisco. He was most recently President of Cherry Street Innovation LLC, an innovation company he founded to identify and develop new growth platforms through new ventures and brand innovation.

Former President Scott Derks will remain with Pilot as Vice President, Operations.

"Collectively, Ross and Keith have created new businesses generating nearly $3 billion revenue and bring tremendous experience in health and nutrition. We are delighted to welcome them to our team," said Chilton.

Pilot Therapeutics is a Nutritional Therapeutics Innovation Company dedicated to the prevention and treatment of chronic inflammatory diseases. Through its Functional Liponomics(TM) discovery platform, Pilot examines the influence of fatty acids on the expression of genes that control the inflammatory and allergic process. Utilizing this technology Pilot has developed a pipeline of medical foods for the prevention and treatment of numerous chronic inflammatory disorders in humans and animals. These innovative products are based on over 60 issued and pending domestic and international patents.

Pilot Therapeutics was founded by Chilton, professor of physiology and pharmacology at Wake Forest University School of Medicine. Chilton is also director of the Wake Forest and Brigham and Women's Program for Botanical Lipids which is supported by a $7.5 million grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements.


'/>"/>
SOURCE Pilot Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. RFID pilot project aims to improve blood banks
2. Pilot fund brings capital to Eau Claire area innovations
3. National $100m pilot program to begin mapping cancer genome
4. Milwaukee health provider network pilots software plan
5. Gateway Technical College pilots IBM training program
6. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
7. Speaker announces business members of IT Task Force
8. Doyle announces technology tax credits for Berbee
9. Doyle announces new energy, global warming policies
10. Doyle announces $80M renewable energy strategy
11. GE announces first installation of Discovery VCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Washington, D.C. (PRWEB) , ... September 19, 2017 ... ... care during an biological outbreak is about to be eliminated, said Lyle Probst, ... makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... technologies for surgical applications, announced today that two new patents have been allowed ... Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore additional clinically-relevant designs ...
(Date:9/17/2017)... ... September 17, 2017 , ... GeneOne Life Science, ... Food and Drug Safety (KMFDS) for an Investigational New Drug application for a ... Syndrome coronavirus (MERS-CoV). The study in Korea represents the second clinical trial for ...
(Date:9/14/2017)... ... September 14, 2017 , ... Boston ... extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to ... In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):